Literature DB >> 24813161

Ovarian reserve and PGD treatment outcome in women with myotonic dystrophy.

N Srebnik1, E J Margalioth2, R Rabinowitz3, I Varshaver2, G Altarescu4, P Renbaum5, E Levi-Lahad4, A Weintraub6, T Eldar-Geva6.   

Abstract

Myotonic dystrophy (DM) is the most common form of muscular dystrophy in adults. There are conflicting reports about its effect on female fertility. This study investigated ovarian reserve and IVF-preimplantation genetic diagnosis (PGD) outcome in women with DM1. A total of 21 women undergoing PGD for DM1 were compared with 21 age- and body mass index-matched women undergoing PGD for other diseases. Ovarian reserve markers, response to stimulation, embryo quality and clinical pregnancy and live birth rates were compared. Day-3 FSH concentration was higher, while anti-Müllerian hormone concentration and antral follicle count were lower in the DM1 group (median, range: 6.9 (1.8-11.3) versus 5.7 (1.5-10.7)IU/l; 0.9 (0.17-5.96) versus 2.68 (0.5-9.1)ng/ml; and 13 (0-63) versus 23 (8-40) follicles, respectively, all P < 0.05). Total FSH dose was higher (5200 versus 2250 IU, P = 0.004), while the numbers of oocytes retrieved (10 versus 16, P < 0.04) and metaphase-II oocytes (9 versus 12, P < 0.03) were lower in the DM1 group. The number of cycles with top-quality embryos and the clinical pregnancy rate were lower in the DM1 group. In conclusion, there is evidence of diminished ovarian reserve and less favourable IVF-PGD outcome in women with DM1. Myotonic Dystrophy (DM) is the most common form of muscular dystrophy in adults. There is evidence of subfertility in males affected with the disease but conflicting reports about the effect of the disease on female fertility. The aim of our study was to investigate ovarian reserve and IVF-PGD results in women with DM. Twenty-one women undergoing preimplantation genetic diagnosis (PGD) treatment for DM were compared to 21 age- and BMI matched women undergoing PGD treatment for other diseases. The two groups were compared for antral follicle count (AFC) and serum anti-Mullerian hormone (AMH) levels (the best known markers of ovarian reserve and fertility potential), ovarian response, embryo quality and pregnancy and live birth rates. AFC and the AMH levels were statistically significant lower in the DM group. Total medication dose needed for ovarian stimulation was higher, the number of oocytes and mature oocytes retrieved, and the number of cycles with top quality embryos were lower in the DM group compared to the controls. In conclusion, there is evidence of diminished ovarian reserve, and less favorable IVF-PGD outcome in women with DM. Therefore, we recommend advising these women about the possibility of early decreasing ovarian function in order to prevent any delay in reproductive planning.
Copyright © 2014 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  IVF; anti-Müllerian hormone; antral follicle count; myotonic dystrophy; ovarian reserve; preimplantation genetic diagnosis

Mesh:

Substances:

Year:  2014        PMID: 24813161     DOI: 10.1016/j.rbmo.2014.03.013

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  8 in total

1.  Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors.

Authors:  Maria Laura Ester Bianchi; Emanuele Leoncini; Marcella Masciullo; Anna Modoni; Shahinaz M Gadalla; Roberto Massa; Emanuele Rastelli; Chiara Terracciano; Giovanni Antonini; Elisabetta Bucci; Antonio Petrucci; Sandro Costanzi; Massimo Santoro; Stefania Boccia; Gabriella Silvestri
Journal:  J Neurol       Date:  2016-01-06       Impact factor: 4.849

2.  The assesment of follicular fluid presepsin levels in poor ovarian responder womenandits relationship with the reproductive outcomes.

Authors:  Ali Ovayolu; Özkan Özdamar; İsmet Gün; Cansev Y Arslanbuğa; Tayfun Kutlu; Gülden Tunalı; Ramazan Uluhan
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study.

Authors:  Nicholas E Johnson; Man Hung; Eriko Nasser; Katharine A Hagerman; Wei Chen; Emma Ciafaloni; Chad R Heatwole
Journal:  J Neuromuscul Dis       Date:  2015-10-07

Review 4.  Fragile X-Associated Diminished Ovarian Reserve and Primary Ovarian Insufficiency from Molecular Mechanisms to Clinical Manifestations.

Authors:  Limor Man; Jovana Lekovich; Zev Rosenwaks; Jeannine Gerhardt
Journal:  Front Mol Neurosci       Date:  2017-09-12       Impact factor: 5.639

5.  Clinical characteristics of pregnancies complicated by congenital myotonic dystrophy.

Authors:  Cheonga Yee; Suk-Joo Choi; Soo-Young Oh; Chang-Seok Ki; Cheong-Rae Roh; Jong-Hwa Kim
Journal:  Obstet Gynecol Sci       Date:  2017-07-14

6.  Preimplantation Genetic Diagnosis for Myotonic Dystrophy Type 1 and Analysis of the Effect of the Disease on the Reproductive Outcome of the Affected Female Patients.

Authors:  Raquel María Fernández; María Dolores Lozano-Arana; Beatriz Sánchez; Ana Peciña; Juan Carlos García-Lozano; Salud Borrego; Guillermo Antiñolo
Journal:  Biomed Res Int       Date:  2017-11-14       Impact factor: 3.411

7.  Anti-Müllerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies.

Authors:  Olesja Parmova; Eva Vlckova; Monika Hulova; Livie Mensova; Igor Crha; Petra Stradalova; Eva Kralickova; Lenka Jurikova; Martina Podborska; Radim Mazanec; Ladislav Dusek; Jiri Jarkovsky; Josef Bednarik; Stanislav Vohanka; Iva Srotova
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

8.  The molecular mechanisms that underlie fragile X-associated premature ovarian insufficiency: is it RNA or protein based?

Authors:  Roseanne Rosario; Richard Anderson
Journal:  Mol Hum Reprod       Date:  2020-10-01       Impact factor: 4.025

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.